X

Given the current situation, we understand that people may experience worry and even fear about how their disease and treatment may impact their personal risk. Sanofi Genzyme is committed to patient safety and to transparent communication. We are taking COVID-19 seriously, and we are committed to updating the communities we serve with relevant information related to our medicines to help inform health decisions.

As COVID-19 has emerged only recently, there are no available data regarding the impact of the virus on our current therapies. At this time, if you have general questions about our therapies, you should consult the current U.S Prescribing Information (USPI).

Each patient’s situation is unique, and patients and their healthcare providers are in the best position to make decisions regarding their care. In addition to local public health authority guidance, and local guidance from medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s (WHO) website.

MAT-US-2001107

INDICATION

AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Do not take AUBAGIO if you have severe liver problems, are pregnant or of childbearing potential and not using effective birth control, have had an allergic reaction to AUBAGIO or leflunomide, or are taking a medicine called leflunomide for rheumatoid arthritis. View IMPORTANT SAFETY INFORMATION

x

Patient Portrayal

WATCH REAL PEOPLE TALK about putting
their relapsing MS in the background

3 ways AUBAGIO 14 mg could help put relapsing MS in the background:

Select one.

AUBAGIO® reduces relapsing MS flare-ups.

Reduced
relapses

AUBAGIO® decreases new active relapsing MS lesions.

Decreased
new lesions

AUBAGIO® slows relapsing MS disability progression.

Slowed
disability
progression*

AUBAGIO was studied in people like You

  • AUBAGIO® was studied versus placebo in 3 clinical trials: TEMSO, TOWER, & TOPIC. AUBAGIO® was studied versus placebo in 3 clinical trials: TEMSO, TOWER, & TOPIC. In 3 clinical trials
  • AUBAGIO® was studied versus placebo with more than 2800 people with relapsing MS. AUBAGIO® was studied versus placebo with more than 2800 people with relapsing MS. With more than 2,800 people
  • AUBAGIO® was studied versus placebo for up to 108 weeks. AUBAGIO® was studied versus placebo for up to 108 weeks. For up to 108 weeks
  • AUBAGIO® was studied versus placebo in both the 14 mg & 7 mg oral doses. AUBAGIO® was studied versus placebo in both the 14 mg & 7 mg oral doses. In doses of 14 mg & 7 mg

AUBAGIO (teriflunomide) 14 mg was shown to be effective vs placebo in 3 key measures: relapses, brain lesions, and disability progression. AUBAGIO 7 mg was shown to be effective vs placebo in 2 of the 3 key measures—relapses and brain lesions.

  • Two clinical trials (Trial 1 and Trial 2) looked at people who had at least 1 or 2 relapses in the 2 years prior to the trial.
  • Clinical Trial 3 looked at people who recently had their first clinical event and had two or more lesions characteristic of relapsing MS.


Clinical Trial 1

1,088 PEOPLE

who had at least 1 relapse during 1 year prior to trial, or 2 relapses during 2 years prior to trial
Clinical Trial 2

1,165 PEOPLE

who had at least 1 relapse during 1 year prior to trial, or 2 relapses during 2 years prior to trial
Clinical Trial 3

614 PEOPLE

who had at least 1 clinical event within 3 months prior to trial, and 2 or more lesions characteristic of relapsing MS

AUBAGIO (teriflunomide) 14 mg was shown to be effective vs placebo in 3 key measures: relapses, brain lesions, and disability progression. AUBAGIO 7 mg was shown to be effective vs placebo in 2 of the 3 key measures—relapses and brain lesions.


AUBAGIO REDUCED RELAPSES

Relapses are new or worsening symptoms, or the return of old symptoms that last 24 hours or more. A relapse can last days, weeks, or months, and it can be mild or severe. But a relapse is always a sign your MS is active.

AUBAGIO Clinical Trials looked at relapses 2 ways:

• How many people had no relapses during the studies (Relapse-Free)

• How often people in the studies had relapses (Relapse Rate)

Clinical Trial 1
57% remained relapse free in clinical trial #1
57%
of people were
relapse-free

on AUBAGIO 14 mg vs 46% on placebo.

54% of people were relapse-free on AUBAGIO 7 mg vs 46% with placebo.


31%
reduction in
relapse rate

with both AUBAGIO 14 mg and 7 mg vs placebo.

Clinical Trial 2
57% remained relapse free in clinical trial #1
57%
of people were
relapse-free

on AUBAGIO 14 mg vs 47% on placebo.

58% were relapse-free on AUBAGIO 7 mg vs 47% with placebo.


36%
reduction in
relapse rate

with AUBAGIO 14 mg and 22% reduction with 7 mg vs placebo.

Clinical Trial 3
72%
of people were
relapse-free

on AUBAGIO 14 mg vs 62% on placebo.

71% were relapse-free on AUBAGIO 7 mg vs 62% with placebo.


AUBAGIO REDUCED RELAPSES OVER TIME

Chart showing relapse rate reduction over time with AUBAGIO in clinical trial 1.

After Clinical Trial 1 ended, people who remained on AUBAGIO 14 mg during the extension study had

About
1 Relapse
over 6 Years
  • The extension study followed people taking AUBAGIO for 5.5 years beyond the original study, for a total of 7.5 years
  • Original clinical study: about 1 relapse over 2 years for people taking placebo
  • Everybody in the extension study took AUBAGIO. Participants who were given a placebo (a pill that does not contain medicine) in the original clinical trial were switched to AUBAGIO
  • The people who stayed in the extension study came in for follow-ups, so researchers could learn more about the long-term safety and effectiveness of AUBAGIO

AUBAGIO DECREASED
NEW LESIONS AND
REDUCED LESION
VOLUME

The appearance of new or enlarging lesions on your MRI are signs that your MS is active and causing damage to your central nervous system.

Clinical Trial 1

Clinical Trial 1 looked at brain lesions as a measure of MS activity. This study looked at lesions 3 ways:

  • The number of new lesions (areas of active inflammation) people had
  • How many people had no new lesions
  • The total area (or volume) of all lesions (including both new and old lesions)

Clinical Trial 1 demonstrated that:

People taking AUBAGIO had

80%
Fewer New
Lesions

with AUBAGIO 14 mg vs 39% with placebo.

57% fewer new lesions with
AUBAGIO 7 mg vs placebo.

For people taking AUBAGIO

64%
were free of
new Lesions

with AUBAGIO 14 mg vs 39% with placebo.

51% were free from new lesions with
AUBAGIO 7 mg vs 39% with placebo.

People had a

69%
reduction in
total Lesion
volume§

with AUBAGIO 14 mg vs placebo.

33% reduction in total lesion volume
with AUBAGIO 7 mg vs placebo.


AUBAGIO SLOWED DISABILITY PROGRESSION

You want to be able to do what you enjoy for as long as possible.

In clinical trials, disability progression was measured using the Expanded Disability Status Scale, or EDSS. The EDSS rates the severity of disability a person has from 0 to 10.* But in everyday life, disability can show itself in small changes in your abilities and the things you do to overcome them. For example: taking the elevator instead of the stairs; parking closer to the supermarket; preferring lighter pots and pans for cooking.


AUBAGIO slowed disability progression in 2 clinical trials.

In Clinical Trial 1 and Clinical Trial 2, AUBAGIO 14 mg was shown to keep more people free from disability progression.

For people taking AUBAGIO:

Clinical Trial 1
80%
Had no
disability
Progression

with AUBAGIO 14 mg vs 73% with placebo.

78% were free of disability progression with
AUBAGIO 7 mg vs 73% with placebo.

Clinical Trial 2
84%
Had no
disability
Progression

with AUBAGIO 14 mg vs 80% with placebo.

79% remained free of disability progression with AUBAGIO 7 mg vs 80% with placebo.


AUBAGIO 14 mg SLOWED DISABILITY PROGRESSION over time

After Clinical Trial 1 ended, of the people who remained
on AUBAGIO 14 mg during the extension study:

61%
Had no disability
Progression for
up to 7.5 Years

Think about what you were doing 2 years ago, and what you can do today. Is your current treatment meeting your needs? Visit EXPLORING TREATMENT to find out. You can also sign up to ATTEND A FREE LIVE EVENT for the opportunity to hear firsthand from someone taking AUBAGIO and expert healthcare providers.

  • The extension study of Clinical Trial 1 followed participants who stayed on AUBAGIO—and those who changed from placebo to AUBAGIO—to examine long-term experience with AUBAGIO
  • The results above are for people who took AUBAGIO during both the clinical trial and the extension study
  • Among people who started with placebo and then changed to AUBAGIO, 59% taking the 14 mg pill and 54% taking the 7 mg pill remained free of disability progression for up to 7.5 years

*Doctors measure disability progression using a test called the Expanded Disability Status Scale, or EDSS. Your first score—or your “baseline”—will determine how your disability is gauged moving forward. If your baseline score is ≤5.5, you’re considered to have sustained disability progression if that score goes up by one point (lasting at least 12 weeks). If your baseline score is >5.5, you’re considered to have sustained disability progression if that score goes up by at least 0.5 points (lasting at least 12 weeks).

The clinical trials were each given a name. Trial 1 was called TEMSO; Trial 2 was called TOWER; and Trial 3 was called TOPIC.

Average Gd-enhanced T1 lesions per scan.

§New and old lesions (T2) plus permanent nerve damage (T1) lesions.

INDICATION

AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION

DO NOT TAKE AUBAGIO IF YOU:
  • Have severe liver problems. AUBAGIO may cause serious liver problems, which can be life-threatening. Your risk may be higher if you take other medicines that affect your liver. Your healthcare provider should do blood tests to check your liver within 6 months before you start AUBAGIO and monthly for 6 months after starting AUBAGIO. Tell your healthcare provider right away if you develop any of these symptoms of liver problems: nausea, vomiting, stomach pain, loss of appetite, tiredness, yellowing of your skin or whites of your eyes, or dark urine.
  • Are pregnant. AUBAGIO may harm an unborn baby. You should have a pregnancy test before starting AUBAGIO. After stopping AUBAGIO, continue to use effective birth control until you have made sure your blood levels of AUBAGIO are lowered. If you become pregnant while taking AUBAGIO or within 2 years after stopping, tell your healthcare provider right away and enroll in the AUBAGIO Pregnancy Registry at 1‑800‑745‑4447, option 2.
  • Are pregnant. AUBAGIO may harm an unborn baby. You should have a pregnancy test before starting AUBAGIO. After stopping AUBAGIO, continue to use effective birth control until you have made sure your blood levels of AUBAGIO are lowered. If you become pregnant while taking AUBAGIO or within 2 years after stopping, tell your healthcare provider right away and enroll in the AUBAGIO Pregnancy Registry at 1-800-745-4447, option 2.
  • Are of childbearing potential and not using effective birth control.

    It is not known if AUBAGIO passes into breast milk. Your healthcare provider can help you decide if you should take AUBAGIO or breastfeed — you should not do both at the same time.

    If you are a man whose partner plans to become pregnant, you should stop taking AUBAGIO and talk with your healthcare provider about reducing the levels of AUBAGIO in your blood. If your partner does not plan to become pregnant, use effective birth control while taking AUBAGIO.

  • Have had an allergic reaction to AUBAGIO or a medicine called leflunomide.
  • Take a medicine called leflunomide for rheumatoid arthritis.

AUBAGIO may stay in your blood for up to 2 years after you stop taking it. Your healthcare provider can prescribe a medicine that can remove AUBAGIO from your blood quickly.

Before taking AUBAGIO, talk with your healthcare provider if you have: liver or kidney problems; a fever or infection, or if you are unable to fight infections; numbness or tingling in your hands or feet that is different from your MS symptoms; diabetes; serious skin problems when taking other medicines; breathing problems; or high blood pressure. Your healthcare provider will check your blood cell count and TB test before you start AUBAGIO. Talk with your healthcare provider if you take or are planning to take other medicines (especially medicines for treating cancer or controlling your immune system), vitamins or herbal supplements.

AUBAGIO may cause serious side effects, including: reduced white blood cell count — this may cause you to have more infections; numbness or tingling in your hands or feet that is different from your MS symptoms; allergic reactions, including serious skin problems; breathing problems (new or worsening); and high blood pressure. Patients with low white blood cell count should not receive certain vaccinations during AUBAGIO treatment and 6 months after.

Tell your doctor if you have any side effect that bothers you or does not go away.

The most common side effects when taking AUBAGIO include: headache; diarrhea; nausea; hair thinning or loss; and abnormal liver test results. These are not all the side effects of AUBAGIO. Tell your healthcare provider about any side effect that bothers you.

Consult your healthcare provider if you have questions about your health or any medications you may be taking, including AUBAGIO.

Please click here for full Prescribing Information, including boxed WARNING and Medication Guide.

IMPORTANT SAFETY INFORMATION
Do not take AUBAGIO if you have severe liver problems. AUBAGIO may cause serious liver problems, which can be life-threatening. Your risk may be higher if you take other medicines that affect your liver. View More